Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

18 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Salivary antibody levels in adolescents in response to a meningococcal serogroup C conjugate booster vaccination nine years after priming: systemically induced local immunity and saliva as potential surveillance tool.
Stoof SP, van der Klis FR, van Rooijen DM, Bogaert D, Trzciński K, Sanders EA, Berbers GA. Stoof SP, et al. Among authors: van rooijen dm, van der klis fr. Vaccine. 2015 Jul 31;33(32):3933-9. doi: 10.1016/j.vaccine.2015.06.055. Epub 2015 Jun 19. Vaccine. 2015. PMID: 26100925
Long-term persistence of protective antibodies in Dutch adolescents following a meningococcal serogroup C tetanus booster vaccination.
van Ravenhorst MB, Marinovic AB, van der Klis FR, van Rooijen DM, van Maurik M, Stoof SP, Sanders EA, Berbers GA. van Ravenhorst MB, et al. Among authors: van rooijen dm, van der klis fr, van maurik m. Vaccine. 2016 Dec 7;34(50):6309-6315. doi: 10.1016/j.vaccine.2016.10.049. Epub 2016 Nov 4. Vaccine. 2016. PMID: 27817957
Meningococcal serogroup C immunogenicity, antibody persistence and memory B-cells induced by the monovalent meningococcal serogroup C versus quadrivalent meningococcal serogroup ACWY conjugate booster vaccine: A randomized controlled trial.
van Ravenhorst MB, van der Klis FRM, van Rooijen DM, Knol MJ, Stoof SP, Sanders EAM, Berbers GAM. van Ravenhorst MB, et al. Among authors: van rooijen dm. Vaccine. 2017 Aug 24;35(36):4745-4752. doi: 10.1016/j.vaccine.2017.06.053. Epub 2017 Jun 28. Vaccine. 2017. PMID: 28668575 Clinical Trial.
SARS-CoV-2 Spike S1-specific IgG kinetic profiles following mRNA or vector-based vaccination in the general Dutch population show distinct kinetics.
van den Hoogen LL, Verheul MK, Vos ERA, van Hagen CCE, van Boven M, Wong D, Wijmenga-Monsuur AJ, Smits G, Kuijer M, van Rooijen D, Bogaard-van Maurik M, Zutt I, van Vliet J, Wolf J, van der Klis FRM, de Melker HE, van Binnendijk RS, den Hartog G. van den Hoogen LL, et al. Sci Rep. 2022 Apr 8;12(1):5935. doi: 10.1038/s41598-022-10020-6. Sci Rep. 2022. PMID: 35396570 Free PMC article.
Immunity against poliomyelitis in the Netherlands, assessed in 2006 to 2007: the importance of completing a vaccination series.
van der Maas NA, Mollema L, Berbers GA, van Rooijen DM, van der Avoort HG, Conyn-Van Spaendonck MA, de Melker HE, van der Klis FR. van der Maas NA, et al. Among authors: van der avoort hg, van rooijen dm, van der klis fr. Euro Surveill. 2014 Feb 20;19(7):20705. doi: 10.2807/1560-7917.es2014.19.7.20705. Euro Surveill. 2014. PMID: 24576472 Free article.
18 results